Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, onc...

Full description

Saved in:
Bibliographic Details
Published in:Front Pharmacol
Main Authors: Vella Bonanno, Patricia, Ermisch, Michael, Godman, Brian, Martin, Antony P., Van Den Bergh, Jesper, Bezmelnitsyna, Liudmila, Bucsics, Anna, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Eriksson, Irene, Fürst, Jurij, Gad, Mohamed, Greičiūtė-Kuprijanov, Ieva, van der Graaff, Martin, Gulbinovic, Jolanta, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Laius, Ott, Langner, Irene, Mardare, Ileana, Markovic-Pekovic, Vanda, Magnusson, Einar, Melien, Oyvind, Meshkov, Dmitry O., Petrova, Guenka I., Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Schuurman, Ad, Ramos, Ricardo, Rodrigues, Jorge, Zara, Corinne, Zebedin-Brandl, Eva, Haycox, Alan
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2017
Subjects:
Pharmacology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572364/
https://ncbi.nlm.nih.gov/pubmed/28878667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00497
Tags: Add Tag
No Tags, Be the first to tag this record!
Loading...

Similar Items